News

€70m fund for EU biotechs
Enlarge image

BusinessEUGermanySwitzerlandUKAustria

€70m fund for EU biotechs

20.09.2012 - The European VC firm Wellington Partners has announced the first closing of a fund exclusively dedicated to investments in EU life sciences companies.

Money for life science companies is coming back to Europe. After Edmond de Rothschild Investment Partners scored €125m for its fourth life sciences fund and Index Ventures announced to put €150m into life sciences companies, now, Wellington Partners (London, Zurich, Munich) has attracted commitments of over  €70m  for its new Wellington Partners IV Life Science Fund. With a target size of €120m, the venture capitalists expect it to be significantly larger than the previous Wellington Partners III Life Science Fund, which raised €78m. Investments will focus on European companies developing innovative medical devices, diagostics and biotechnology.

According to Wellington’s investment team, the new fund attracted investors from Germany, Switzerland, Austria, Benelux, France, the UK, the US and the Middle East, among them the European Investment Fund (EIF), LfA Förderbank Bayern, Austria Wirtschaftsservice GmbH and certain large family offices.

Dr. Rainer Strohmenger, General Partner at Wellington Partners, said that the closing was a "big success in a challenging financial environment". For investors who are willing to act anti-cyclically, the sector would „provide the opportunity to generate outstanding returns.“

Wellington Partners’ portfolio already comprises some successful European life sciences players, amongst them Swiss Actelion or German mtm laboratories, which was swallowed by Roche last year for up to €190m. Other players include: Cancer vaccine developer immatics, medtech company Invendo Medical, diagnostics specialist Oxford Immunotec, and heart valve developer Symetis. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/wellington-partners-closes-eur70m-fund.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.28 CHF7.54%
  • FORMYCON29.50 EUR3.91%
  • EPIGENOMICS5.72 EUR3.06%

FLOP

  • CYTOS0.64 CHF-3.03%
  • VITA 345.65 EUR-2.59%
  • BAYER133.40 EUR-2.56%

TOP

  • SYNGENTA423.60 CHF29.8%
  • EVOLVA1.82 CHF19.0%
  • BASILEA131.30 CHF16.1%

FLOP

  • CYTOS0.64 CHF-34.7%
  • MEDIGENE8.55 EUR-18.2%
  • 4SC4.55 EUR-12.5%

TOP

  • WILEX4.07 EUR408.8%
  • FORMYCON29.50 EUR335.1%
  • 4SC4.55 EUR299.1%

FLOP

  • MOLOGEN4.93 EUR-53.7%
  • PAION2.52 EUR-27.4%
  • BIOFRONTERA2.25 EUR-26.9%

No liability assumed, Date: 28.05.2015